Menu
Clinical Applications: Alzheimer's Disease
NucleoCapture® for Alzheimer Disease
NucleoCapture® mode of action
Circulating NETs have been recently reported as a major source of amyloid. Synthesis of amyloid occurs in neutrophils primed for NETs production. Large quantities of amyloid are present on the circulating NET backbone. NucleoCapture® treatment selectively remove NETs and amyloid attached to NETs thereby offering an alternative amyloid neutralizing strategy.
Clinical development
In a series of clinical cases involving compassionate use of NucleoCapture® it was shown that up to 60mg of amyloid can be removed from patient blood during 2-hour NucleoCapture® treatment session.
An exploratory clinical trial to assess the effects of NucleoCapture® on amyloid removal in healthy volunteers, Alzheimer’s disease and Parkinson disease patients is currently recruiting participants.
Image Credit: Clin Exp Immunol. 2016 Mar;183(3):469-79
